By DoctoRx : Background : Gilead Sciences ( GILD ) may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years. The following shows GILD versus the S&P 500 and the NASDAQ since this Yahoo! Finance chart begins with ...
By Trefis : Merck's ( MRK ) legacy pharmaceuticals and consumer business constitutes roughly 30% of the company's value according to our estimates. Despite it being a segment that has seen a revenue decline in recent years, its value contribution remains high due to much higher sales compared to ...
MRK ) is another company that has conducted some recent M&A activity, with its proposed acquisition of Idenix Pharmaceuticals , Inc. for $3.85 billion . Merck is hoping this acquisition provides it with a serious hepatitis C contender
good chance that this could happen with Keryx Biopharmaceuticals ( KERX ). The reason is because Baupost Group, of Idenix ( IDIX ) fame, has recently acquired an over 10% stake in KERX and has become its largest shareholder. As explained by Market Realist
By Austrolib: Merck's ( MRK ) acquisition of Idenix ( IDIX ) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have
Merck ( MRK ) begins the process of acquiring Idenix Pharmaceuticals ( IDIX ) for $24.50 in cash. It will file a Schedule ..... 14D-9 that includes the recommendation of the IDIX BOD that shareholders accept MRK's offer. Post
takeover activity. Monday, Merck ( MRK ) announced that it is going to acquire the development-stage biopharma company Idenix ( IDIX ) for nearly $4 B. Actavis ( ACT ) is acquiring fallen angel Forest Labs ( FRX ) at a high valuation. Amongst the giants
billion in sales for its new $1000 hepatitis C pill, Solvadi. It's also why Merck ( MRK ) acquired Idenix Pharmaceuticals Inc. ( IDIX ) earlier this month. The list of companies developing hepatitis C medication includes the aforementioned
Ronald Burns files suit (Burns vs Idenix Pharmaceuticals ) attempting to block its $3.9B acquisition of Idenix ( IDIX +1.4% ) stating that the price undervalues IDIX . He cites IDIX 's intrinsic value and a flawed
Fabian : The recent buyout of Idenix Pharmaceuticals ( IDIX ) by drug maker Merck & Co ..... 230% single-day gain that IDIX experienced as a result of the ..... modified equal-weighted index, IDIX had a much larger impact on the